Restarting Invega 6 mg: Direct Approach
Start paliperidone (Invega) 6 mg once daily immediately without dose titration, as this is the FDA-approved recommended starting dose for most patients with schizophrenia or schizoaffective disorder 1.
Dosing Strategy
The 6 mg dose represents the standard initiation point because:
- No titration required: Paliperidone ER is specifically designed to be started at therapeutic doses without gradual escalation 1, 2
- Optimal balance: This dose provides efficacy while minimizing dose-related adverse effects like extrapyramidal symptoms (EPS) and tachycardia 1
- Flexible adjustment: The approved range is 3-12 mg daily, allowing individualization based on response 1, 2
When to Adjust the Initial 6 mg Dose
Consider starting at 3 mg instead if:
- Patient is elderly or frail
- History of significant EPS or tolerability issues with previous antipsychotics
- Severe renal impairment (CrCl 50-79 mL/min: start 3 mg, max 6 mg; CrCl 10-49 mL/min: start 1.5 mg, max 3 mg) 1
- Recently diagnosed/first-episode patients 3, 4
Consider starting at 9-12 mg if:
- Acute psychotic symptoms requiring more aggressive treatment 3, 4
- Previous antipsychotic was insufficient at standard doses
- Patient previously stable on higher paliperidone doses 3
Switching from Other Antipsychotics
If switching from risperidone specifically:
- Higher paliperidone doses may be needed than the equivalent risperidone dose 5
- A patient on risperidone 3 mg may require paliperidone 9 mg (not 6 mg) to maintain similar plasma levels 5
- Monitor for symptom worsening in the first 1-2 weeks if using standard 6 mg dose 5
Cross-tapering approach (preferred over abrupt switch):
- Start paliperidone 6 mg while gradually tapering the previous antipsychotic over 1-2 weeks 3
- For antipsychotics with high sedative/anticholinergic properties (quetiapine, olanzapine, chlorpromazine): taper more slowly to avoid withdrawal symptoms 3
- For antipsychotics with minimal sedation (aripiprazole, ziprasidone): can taper more rapidly 3
Monitoring After Restart
Assess efficacy at 4 weeks on the chosen dose 6:
- If inadequate response with good adherence, increase dose by 3 mg increments (max 12 mg)
- If intolerable side effects, reduce to 3 mg or switch to alternative antipsychotic
Key adverse effects to monitor 1:
- EPS (dose-related; risk increases above 6 mg)
- Tachycardia (common at all doses)
- Orthostatic hypotension (especially first few days)
- QTc prolongation (obtain baseline ECG if cardiac risk factors)
- Weight gain and metabolic changes (monitor glucose, lipids)
- Hyperprolactinemia
Critical Safety Considerations
- Take with or without food (unlike some antipsychotics, food does not significantly affect absorption) 2
- Swallow tablets whole - do not crush, chew, or divide (OROS delivery system) 1
- Peak levels occur at 24 hours, so once-daily dosing maintains stable concentrations 2, 7
- Steady state reached in 4-5 days due to 23-hour half-life 2
The 6 mg starting dose is evidence-based and appropriate for most clinical scenarios when restarting paliperidone, with adjustments made based on specific patient factors rather than routine titration.